Financials Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/12/2025 GMT			5-day change	1st Jan Change
6.600 ^USD	-2.22%		+26.92%	+37.79%

12-04	Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study	MT
12-04	FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug	DJ

Projected Income Statement: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	248.2	268.7	254.4	192.6	198.8	218.2	265.4	329.9
Change	-	8.27%	-5.32%	-24.27%	3.18%	9.76%	21.67%	24.28%
EBITDA	-	45.01	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
EBIT ¹	27.24	42.16	6.329	-13.95	-40.66	-143.1	-127.8	-69.9
Change	-	54.8%	-84.99%	-320.45%	-191.43%	-251.94%	10.69%	45.31%
Interest Paid	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	31.66	42.36	11.3	6.339	-22.92	-127.5	-93.8	-60.57
Change	-	33.83%	-73.33%	-43.9%	-461.59%	-456.26%	26.43%	35.43%
Net income ¹	23.34	33.15	6.275	2.509	-18.9	-136.3	-92.07	-60.23
Change	-	42.06%	-81.07%	-60.02%	-853.29%	-620.95%	32.43%	34.58%
Announcement Date	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	67.65	-	67.9	70.1	68.02	60.19	64.39	65.32	64.48	46.06	38.82	45.27	-	50.47	47.65	53.18	50.04	52.59	56.26	59.28	61.47	64.93	69.37	73.73
Change	-	-	-	3.23%	-2.96%	-11.51%	6.97%	1.44%	-1.28%	-28.58%	-15.72%	16.63%	-	-	-5.59%	11.61%	-5.91%	5.09%	6.97%	5.36%	3.7%	5.64%	6.83%	6.3%
EBITDA	-	-	16.82	15.48	9.342	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-7.98%	-39.64%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	10.45	-	12.37	10.82	8.636	-7.669	3.461	3.908	6.629	-2.867	-5.995	-7.094	-	-10.15	-11	-10.28	-41.03	-38.5	-31.28	-32.23	-33.5	-33.15	-33.25	-32.95
Change	-	-	-	-12.53%	-20.18%	-188.8%	145.13%	12.92%	69.63%	-143.25%	-109.1%	-18.33%	-	-	-8.42%	6.55%	-299.14%	6.15%	18.75%	-3.03%	-3.93%	1.04%	-0.3%	0.9%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	10.92	10.43	12.6	10.72	8.61	-7.564	3.79	5.461	9.613	2.592	-0.12	-1.661	-	-5.516	-6.244	-6.497	-37.37	-34.89	-28.39	-26.74	-30.6	-30.55	-30.95	-30.8
Change	-	-4.54%	20.87%	-14.93%	-19.7%	-187.85%	150.11%	44.09%	76.03%	-73.04%	-104.63%	-1,284.17%	-	-	-13.2%	-4.05%	-475.16%	6.64%	18.62%	5.82%	-14.44%	0.16%	-1.31%	0.48%
Net income ¹	8.19	8.65	9.653	7.771	7.078	-6.43	2.574	3.27	6.861	1.52	0.137	-2.4	-4.146	-4.518	-5.324	-4.912	-29.49	-27.21	-22.59	-56.79	-30.6	-30.55	-30.95	-30.8
Change	-	5.62%	11.6%	-19.5%	-8.92%	-190.84%	140.03%	27.04%	109.82%	-77.85%	-90.99%	-1,851.82%	-72.75%	-8.97%	-17.84%	7.74%	-500.45%	7.75%	16.98%	-151.43%	46.12%	0.16%	-1.31%	0.48%
Announcement Date	10/02/21	05/05/21	28/07/21	03/11/21	23/02/22	05/05/22	03/08/22	02/11/22	08/02/23	27/07/23	08/11/23	07/02/24	09/05/24	31/07/24	06/11/24	13/02/25	07/05/25	31/07/25	29/10/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-

Estimates

Cash Flow Forecast: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2024	2025	2026	2027
CAPEX ¹	4.719	1	1	1
Change	-	-78.81%	0%	0%
Free Cash Flow (FCF) ¹	-20.48	-111	-115	-71
Change	-	-442.1%	-3.6%	38.26%
Announcement Date	13/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	16.75%	-	-	-	-	-	-
EBIT Margin (%)	-	10.98%	15.69%	2.49%	-7.24%	-20.46%	-65.59%	-48.14%	-21.19%
EBT Margin (%)	-	12.76%	15.77%	4.44%	3.29%	-11.53%	-58.44%	-35.33%	-18.36%
Net margin (%)	-	9.4%	12.34%	2.47%	1.3%	-9.51%	-62.46%	-34.69%	-18.26%
FCF margin (%)	-	-	-	-	-	-10.3%	-50.88%	-43.32%	-21.52%
FCF / Net Income (%)	-	-	-	-	-	108.34%	81.46%	124.9%	117.87%
Profitability
ROA	3.49%	3.35%	4.68%	0.64%	-1.36%	-3.9%	-	-	-
ROE	33.67%	5.4%	6.92%	1.22%	0.47%	-3.49%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	2.37%	0.46%	0.38%	0.3%
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-23.05%	-0.9%	-0.87%	-1.41%
Items per share
Cash flow per share ¹	-	-	1.128	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	0.42	0.58	0.11	0.04	-0.33	-2.308	-1.538	-0.9767
Change	-	-	38.1%	-81.03%	-63.64%	-925%	-599.24%	33.37%	36.48%
Nbr of stocks (in thousands)	-	54,692	55,712	56,590	57,532	58,308	59,097	59,097	59,097
Announcement Date	-	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-